Biocept, Inc. (BIOC) is an interesting player in the Healthcare space, with a focus on Medical Laboratories & Research. The stock has been active on the tape, currently trading at $0.19, down from yesterday’s close by -13.64%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Biocept, Inc. (BIOC) currently trades with a market capitalization of $12.70 Million. That value represents a market adjusting for revenues that have been falling by -52.06 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$21.06 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -$0.09 on a per share basis this quarter. Perhaps, that suggests something about why 0.78% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Biocept, Inc. recorded a 52-week high of $1.85. It is now trading 1.66% off that level. The stock is trading $0.26 its 50-day moving average by 0.07%. The stock carved out a 52-week low down at $0.18.
In recent action, Biocept, Inc. (BIOC) has made a move of -24.00% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.61, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 8.51% with $66.82 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of BIOC.